INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2015

Adding curcumin to mesalamine therapy induced higher rates of clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis.

Fifty patients with active mild-to-moderate ulcerative colitis unresponsive to maximum mesalamine therapy were randomized to receive curcumin capsules (3 g/day, n = 26) or identical placebo (n = 24) for 1 month alongside mesalamine. In the intention-to-treat analysis, 53.8% (14/26) of patients in the curcumin group achieved clinical remission at week 4 compared with 0% (0/24) in the placebo group (P = .01; OR, 42; 95% CI, 2.3-760). Clinical response occurred in 65.3% of the curcumin group vs. 12.5% in the placebo group (P < .001). Endoscopic remission was observed in 38% (8/22) evaluated in the curcumin group vs. 0% (0/16) in the placebo group (P = .043). Adverse events were rare and comparable between groups.

Study type
Multicenter randomized, placebo-controlled, double-blind trial
Who was studied
50 mesalamine-treated patients with active mild-to-moderate ulcerative colitis unresponsive to maximum-dose mesalamine
What was measured
Clinical remission (SCCAI <=2) at week 4; clinical and endoscopic responses

THE PAPER

Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.

Lang A, Salomon N, Wu JC, Kopylov U, Lahat A, Har-Noy O, Ching JY, Cheong PK, Avidan B, Gamus D, Kaimakliotis I, Eliakim R, Ng SC, Ben-Horin S. Clin Gastroenterol Hepatol, 2015.

PubMed 25724700 ↗DOI 10.1016/j.cgh.2015.02.019 ↗

Gut & microbiome

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.